SCHEDULE: Glazer Capital Divests Entire Stake in SpringWorks Therapeutics, Falling Below 5% Ownership Threshold

Glazer Capital, LLC and Paul J. Glazer have reported that their beneficial ownership in SpringWorks Therapeutics, Inc. has fallen to 0.00%, triggering a Schedule 13G filing.

Summary

• The filing is a Schedule 13G for SpringWorks Therapeutics, Inc. (CUSIP: 85205L107), regarding its Common Stock.
• The reporting persons are Glazer Capital, LLC, a Delaware limited liability company, and Paul J. Glazer, a United States citizen, who serves as the Managing Member of Glazer Capital.
• Glazer Capital, LLC acts as an investment manager for certain funds and managed accounts (the 'Glazer Funds').
• As of June 30, 2025, the date of the event requiring this filing, the reporting persons ceased to be the beneficial owner of more than five percent of the class of securities.
• The aggregate amount beneficially owned by each reporting person is 0.00 shares, representing 0.00% of the class.
• The securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 3

Explanation: The filing indicates that Glazer Capital and Paul J. Glazer have divested their entire stake in SpringWorks Therapeutics, Inc., which previously exceeded 5%. This divestment by a significant institutional investor can be perceived as a negative signal.

Negatives

• Glazer Capital, LLC and Paul J. Glazer, who previously held over 5% of SpringWorks Therapeutics, Inc. common stock, have reported that their beneficial ownership has fallen to 0.00%, indicating a complete divestment of their stake.

Future Outlook

No forward-looking statements or guidance regarding SpringWorks Therapeutics' future are provided in this ownership disclosure.

Management Comments

• Paul J. Glazer, Managing Member of Glazer Capital, LLC, certified that, to the best of his knowledge and belief, the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

This filing is a standard disclosure of a change in beneficial ownership by an institutional investor, reflecting a divestment of their stake in SpringWorks Therapeutics, Inc. It does not provide broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders may interpret the complete divestment of a significant stake by Glazer Capital as a negative signal regarding the company's future prospects or valuation, potentially influencing stock price.

Key Dates

Recommendation

Keywords

SpringWorks Therapeutics, Glazer Capital, Schedule 13G, beneficial ownership, common stock, SEC filing, institutional investor, ownership change